Amy Bultynck
About Amy Bultynck
Amy Bultynck is an Executive Cell Therapy Account Specialist with extensive experience in hematology and oncology. She has worked at various pharmaceutical companies, including Kite Pharma and Gilead Sciences, and has a background in food marketing and Spanish studies.
Current Role at Kite Pharma
Amy Bultynck serves as the Executive Cell Therapy Account Specialist at Kite Pharma, a position she has held since 2022. In this role, she focuses on promoting advanced cell therapies, particularly Yescarta, which is a first-in-class CAR T therapy for adults with relapsed or refractory Diffuse Large B-Cell Lymphoma. Her responsibilities include educating healthcare professionals about the therapy's indications and benefits.
Previous Experience at Kite Pharma
Prior to her current role, Amy worked at Kite Pharma as the Unbranded CAR T Speaker Deck Creator for seven months in 2022. During this time, she developed materials to support the promotion of Yescarta for various indications, including second-line relapsed/refractory Diffuse Large B-Cell Lymphoma and relapsed/refractory Follicular Lymphoma.
Career Background in Pharmaceuticals
Amy Bultynck has extensive experience in the pharmaceutical industry. She worked at Gilead Sciences for eight years as a Senior Cell Therapy Account Specialist in Hematology/Oncology and previously held roles as a Senior Therapeutic Specialist for Ischemic Heart Disease. Additionally, she spent ten years at Daiichi Sankyo, Inc. as a Senior Cardiovascular Hospital Sales Representative.
Educational Background
Amy studied at Western Michigan University, where she earned a Bachelor of Business Administration (BBA) with a focus on Food Marketing and Spanish from 1995 to 1999. She is also pursuing a Spanish Major at La Universidad de Alicante in Spain, where she has been studying since 1999.
Launch of CAR T Therapy
During her career, Amy played a significant role in the launch of CAR T therapy Tecartus, which is indicated for relapsed/refractory Mantle Cell Lymphoma and relapsed/refractory Adult Acute Lymphoblastic Leukemia. This initiative highlights her expertise in cell therapy and her contributions to advancing treatment options in hematology.